Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KYMR Kymera Therapeutics, Inc.

盘后交易 05-01 17:23:16 EDT

80.71

-0.36

-0.44%

盘后80.71

+0.000.00%

17:13 EDT

最高82.54	最低79.57	成交量69.36万
今开81.51	昨收81.07	日振幅3.66%
总市值65.89亿	流通市值44.09亿	总股本8,164万
成交额5,616万	换手率1.27%	流通股本5,463万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":80.71,"timestamp":1777665600000,"preClose":81.07,"halted":0,"volume":693608,"hourTrading":{"tag":"盘后","latestPrice":80.71,"preClose":80.71,"latestTime":"17:13 EDT","volume":28092,"amount":2268573.9547200003,"timestamp":1777670036843,"change":0,"changeRate":0,"amplitude":0.00446},"delay":0,"changeRate":-0.004440606882940662,"floatShares":54626600,"shares":81642394,"eps":-3.69,"marketStatus":"盘后交易","change":-0.36,"latestTime":"05-01 17:23:16 EDT","open":81.51,"high":82.54,"low":79.5701,"amount":56164082.40648,"amplitude":0.036634,"askPrice":90.91,"askSize":100,"bidPrice":64.93,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.69,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1777680000000},"marketStatusCode":4,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":81.07,"preHourTrading":{"tag":"盘前","latestPrice":81.69,"preClose":81.07,"latestTime":"09:29 EDT","volume":1993,"amount":161633.53566000002,"timestamp":1777642199999,"change":0.62,"changeRate":0.007648,"amplitude":0.04934},"postHourTrading":{"tag":"盘后","latestPrice":80.71,"preClose":80.71,"latestTime":"17:13 EDT","volume":28092,"amount":2268573.9547200003,"timestamp":1777670036843,"change":0,"changeRate":0,"amplitude":0.00446},"volumeRatio":1.206601,"impliedVol":0.6705,"impliedVolPercentile":0.3307},"requestUrl":"/m/hq/s/KYMR","defaultTab":"news","newsList":[{"id":"1138387402","title":"Kymera Therapeutics公司KT-621治疗特应性皮炎的BROADEN2二期B阶段试验进行中，数据预计2027年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1138387402","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138387402?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:03","pubTimestamp":1776078205,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公司宣布，其重点候选药物KT-621针对中重度特应性皮炎的BROADEN2二期B阶段临床试验目前正在顺利推进中。该项关键研究旨在进一步评估该疗法的有效性与安全性。\n根据公司公布的时间表，这项试验的顶线数据结果预计将在2027年中期获得。数据的公布将成为验证KT-621临床潜力的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144121811","title":"Kymera Therapeutics获美国FDA授予KT-621快速通道资格，该口服Stat6降解剂为治疗中重度哮喘的首创疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1144121811","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144121811?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:03","pubTimestamp":1776078199,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.（简称Kymera Therapeutics）宣布，其首创口服Stat6降解剂KT-621获得美国食品药品监督管理局（FDA）的快速通道资格，用于治疗中重度哮喘患者。这一重要进展有望加速该创新疗法的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108680007","title":"Kymera Therapeutics宣布吉利德科学行使选择权，获得口服Cdk2分子胶降解剂候选药物KT-200授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1108680007","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108680007?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:02","pubTimestamp":1775732525,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics, Inc.今日宣布，其合作伙伴吉利德科学已正式行使选择权，获得口服Cdk2分子胶降解剂开发候选药物KT-200的授权许可。这一决定标志着双方在创新肿瘤疗法合作中的重要里程碑。通过分子胶降解技术，KT-200旨在高效降解致病蛋白，为肿瘤治疗提供新机制。此次选择权的行使，不仅验证了Kymera Therapeutics在蛋白质降解领域的研发实力，也为吉利德科学扩充其肿瘤管线增添了重要资产。双方将继续推进该候选药物的后续开发工作，加速其向临床应用的转化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115634896","title":"Kymera Therapeutics公布KT-621一期B组数据，将在美国皮肤病学会年会进行重磅口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1115634896","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115634896?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:02","pubTimestamp":1773140575,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公司宣布，其研发的KT-621一期B组临床试验数据被选为美国皮肤病学会（AAD）年会上的重磅口头报告环节。这一突破性进展凸显了该疗法在皮肤病领域的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104281611","title":"异动解读 | 强劲财报与充足现金储备提振信心，Kymera Therapeutics盘中大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104281611","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104281611?lang=zh_cn&edition=full","pubTime":"2026-02-27 04:55","pubTimestamp":1772139313,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.（KYMR）今日盘中股价大幅上涨5.04%，市场表现活跃。消息面上，公司于盘前正式公布了2025年第四季度及全年财务业绩，并同步更新了业务进展。报告显示，公司财务状况稳健，截至2025年12月31日，持有的现金储备高达16亿美元。这一充足的资金为其未来的研发和运营提供了坚实保障，预计足以支持公司各项业务推进至2029年。强劲的财务表现和充裕的现金状况，有效增强了投资者对公司长期发展潜力的信心，从而推动了股价在交易时段的显著上扬。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171937452","title":"异动解读 | 股东拟出售3139万股，Kymera Therapeutics盘前大跌7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171937452","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171937452?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:28","pubTimestamp":1772112516,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics, Inc.今日盘前股价大幅下挫7.88%，引起了市场的广泛关注。消息面上，根据美国证券交易委员会披露的文件显示，Kymera Therapeutics的部分现有股东计划出售总计3139万股公司普通股。此类由股东发起的售股行为将增加市场中的股票供应量，通常被视为潜在的利空信号，可能引发投资者对公司股票未来走势的担忧，从而导致股价承压下跌。需要指出的是，此次售股由公司股东发起，而非公司发行新股，因此Kymera Therapeutics公司自身不会从此次售股中获得任何收益。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155188159","title":"Kymera Therapeutics公司 - 股东拟出售3139万股普通股 - 美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1155188159","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155188159?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:27","pubTimestamp":1772112453,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，生物技术公司Kymera Therapeutics, Inc. 的部分现有股东计划出售总计3139万股公司普通股。\n此次售股行为由公司股东发起，而非公司发行新股，因此Kymera Therapeutics公司自身不会从此次售股中获得任何收益。此类股东减持行为通常会引起市场对公司股票未来供应量及股价潜在波动的关注。投资者需密切关注后续市场动态及相关公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131455532","title":"Kymera Therapeutics, Inc. 财务状况稳健：截至2025年12月31日持有16亿美元现金，资金可支撑至2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1131455532","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131455532?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:18","pubTimestamp":1772108303,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. 展现出强劲的财务实力。截至2025年12月31日，公司持有的现金储备高达16亿美元。这一充足的资金为其未来的研发和运营提供了坚实保障，预计足以支持公司各项业务推进至2029年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146980037","title":"Kymera Therapeutics公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1146980037","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146980037?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:13","pubTimestamp":1772108026,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.（简称\"Kymera Therapeutics\"）近日正式披露了其2025年第四季度及全年的财务报告，同时向市场通报了公司最新的业务动态。此次公布涵盖了公司在关键财务指标上的表现，以及研发管线、战略合作等方面的进展，为投资者提供了全面的运营概览。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143087468","title":"Kymera Therapeutics宣布首例患者完成KT-621给药——首创口服Stat6降解剂进入Breadth二期B阶段哮喘临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1143087468","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143087468?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:01","pubTimestamp":1769688060,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics宣布，其创新药物KT-621已完成针对哮喘患者的首例给药，标志着该口服Stat6降解剂正式进入Breadth二期B阶段临床试验。作为同类首创疗法，KT-621通过靶向降解Stat6蛋白来调节免疫反应，为中重度哮喘患者提供潜在治疗选择。此次临床试验旨在评估KT-621的安全性、耐受性及有效性，预计将纳入多国临床研究中心的重症哮喘患者。该阶段试验数据的收集与分析，将为后续全球临床开发策略提供关键依据。Stat6信号通路在过敏性炎症疾病中扮演核心角色。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104376733","title":"Kymera Therapeutics Inc. 计划于2026年推进至少一款首创口服免疫学项目的新开发候选药物进入IND阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1104376733","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104376733?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:07","pubTimestamp":1768306058,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Inc. 近日公布了其研发管线的重要规划，公司计划在2026年前推进至少一款针对首创（First-in-Class）口服免疫学项目的新开发候选药物，旨在向新药临床试验申请（IND）阶段迈进。这一战略部署凸显了公司致力于在免疫治疗领域开拓创新疗法的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194110609","title":"Kymera Therapeutics开展的皮炎治疗试验取得了积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1194110609","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194110609?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:40","pubTimestamp":1765197643,"startTime":"0","endTime":"0","summary":"实现了深度STAT6降解。","market":"us","thumbnail":"https://static.tigerbbs.com/08ecfd9eac9c3137da2cc8b5e8e15cc0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/08ecfd9eac9c3137da2cc8b5e8e15cc0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"131f4a8ae97812e1f16587f8e011d27b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kymera Therapeutics开展的皮炎治疗试验取得了积极进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194478362","title":"盘前｜CFLT、KYMR暴涨，CoreWeave“跳水”，特斯拉跌超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194478362","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194478362?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:27","pubTimestamp":1765196866,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前交易时段小幅上涨。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFLT","CVNA","KYMR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1153788539","title":"Kymera Therapeutics, Inc. - 在KT-621治疗中观察到所有疾病终点的强健临床活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1153788539","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153788539?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:07","pubTimestamp":1765195631,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. - 在KT-621治疗中观察到所有疾病终点的强健临床活性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"131f4a8ae97812e1f16587f8e011d27b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118432812","title":"Kymera Therapeutics Inc - KT-621 Broaden2 II期B试验针对严重的阿尔茨海默病仍在进行中，数据预计于2027年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1118432812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118432812?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:04","pubTimestamp":1765195482,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Inc - KT-621 Broaden2 II期B试验针对严重的阿尔茨海默病仍在进行中，数据预计于2027年中公布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191653930","title":"Kymera Therapeutics公布KT-621的第一阶段B临床试验取得积极结果，该药为首个口服Stat6降解剂，适用于中重度特应性皮炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1191653930","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191653930?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:03","pubTimestamp":1765195430,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公布KT-621的第一阶段B临床试验取得积极结果，该药为首个口服Stat6降解剂，适用于中重度特应性皮炎患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"131f4a8ae97812e1f16587f8e011d27b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143730690","title":"Kymera Therapeutics将在2025年12月8日公布KT-621扩展1B期特应性皮炎试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1143730690","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143730690?lang=zh_cn&edition=full","pubTime":"2025-12-06 05:02","pubTimestamp":1764968524,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics将在2025年12月8日公布KT-621扩展1B期特应性皮炎试验结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129014922","title":"Kymera Therapeutics首位患者在Broaden2 II期B临床试验中接受KT-621治疗，这是一种首创的口服Stat6降解剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1129014922","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129014922?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:02","pubTimestamp":1764072160,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics首位患者在Broaden2 II期B特应性皮炎临床试验中接受KT-621治疗，这是一种首创的口服Stat6降解剂","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517437281","title":"Kymera Therapeutics, Inc.2024财年实现净利润-2.24亿美元，同比减少52.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517437281?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363235,"startTime":"0","endTime":"0","summary":"3月8日，Kymera Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.24亿美元，同比减少52.38%；其中营业收入为47.07百万美元，同比减少40.11%，每股基本收益为-2.98美元。从资产负债表来看，Kymera Therapeutics, Inc.总负债1.42亿美元，其中短期债务13.11百万美元，资产负债比为6.89，流动比率为0.08。机构评级：截至2025年3月8日，当前有17家机构对Kymera Therapeutics, Inc.目标价做出预测，其中目标均价为58.82美元，其中最低目标价为41.00美元，最高目标价为97.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYMR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147904941","title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147904941","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147904941?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:10","pubTimestamp":1740669010,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics今日盘中股价大幅下跌7.27%,引发市场广泛关注。据统计,截至收盘KYMR报33.34美元,成交量3.18万股,振幅4.84%。公司最新公布的2024年第四季度财报显示,KYMR当季每股亏损0.88美元,远高于华尔街分析师预期的0.78美元亏损。与去年同期相比,营收更是大幅下滑84.56%。显而易见,Kymera Therapeutics业绩大幅逊于市场预期,给投资者带来了较大的不确定性和失望。公司财务数据的疲软表现,可能是导致KYMR股价今日大跌的主要诱因之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":-0.07},{"period":"1month","weight":-0.0267},{"period":"3month","weight":0.1153},{"period":"6month","weight":0.311},{"period":"1year","weight":1.3656},{"period":"ytd","weight":0.0419}],"compareEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0.1051},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0537},{"period":"1year","weight":0.296},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kymera Therapeutics, Inc.是一家有限责任公司，于2017年5月25日根据特拉华州法律成立。该公司是一家生物制药公司，专注于发现和开发新型小分子疗法，利用人体自身的天然蛋白质降解系统选择性地降解致病蛋白。该公司拥有专有的靶向蛋白质降解平台，名为Pegasus，能够发现对全身致病蛋白具有强效活性的高选择性小分子蛋白质降解剂。该公司认为，其小分子蛋白质降解剂相比现有疗法具有显著优势，能够针对此前传统疗法难以触及的人类基因组的大部分区域进行治疗。该公司专注于已通过临床验证但关键生物节点/蛋白质尚未被药物靶向或药物靶向效果不佳的生物通路。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.060685},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.014692},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.075866},{"month":4,"riseRate":0.5,"avgChangeRate":0.006528},{"month":5,"riseRate":0.2,"avgChangeRate":-0.147131},{"month":6,"riseRate":0.6,"avgChangeRate":0.114241},{"month":7,"riseRate":0.8,"avgChangeRate":0.172329},{"month":8,"riseRate":0.6,"avgChangeRate":0.035263},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.031798},{"month":10,"riseRate":0.666667,"avgChangeRate":0.069597},{"month":11,"riseRate":0.666667,"avgChangeRate":0.180891},{"month":12,"riseRate":0.666667,"avgChangeRate":0.094258}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}